Jack Modell, M.D.

Vice President and Senior Medical Officer

Jack Modell

Jack Modell, M.D.

Vice President and Senior Medical Officer

A board-certified psychiatrist with nearly 40 years of experience in clinical research, Dr. Jack Modell has spent a considerable amount of time within both the academia and pharmaceutical/CRO sides of the industry. Pairing his 20 years of teaching, providing patient care, and conducting clinical research with 19 years of clinical drug development experience – proof of concept through market support, medical affairs, successful NDA filings, medical governance, drug safety, compliance, and management – it’s easy to see why Dr. Modell has received several awards and honors for both research and clinical care.

While there are few therapeutic areas in which Dr. Modell doesn’t have experience, his greatest expertise lies in the neurosciences. After completing his residency in Psychiatry at the University of Vermont, Dr. Modell completed a fellowship at the University of Michigan in neuroimaging and anxiety disorders. He then joined the UM psychiatry faculty where he helped elucidate the role of the basal ganglia in obsessive compulsive disorder and alcoholism. While there, Dr. Modell also developed the YBOCS-hd scale to quantify the obsessive and compulsive characteristics of heavy drinking. Continuing his academic career and neuroimaging research at the University of Alabama at Birmingham, Dr. Modell treated patients with a variety of neuropsychiatric disorders including severe depression and anxiety – ultimately attaining the rank of tenured professor of psychiatry.

In 2001, Dr. Modell left clinical medicine and joined GlaxoSmithKline. As a senior director and then vice president in neurosciences, he was involved with numerous clinical development programs in both psychiatry and neurology, but particularly in depression. During his tenure at GSK, Dr. Modell and his research team developed the first and only medication to be approved for the prevention of depressive episodes in patients who suffer from seasonal affective disorder.

Along with serving on numerous advisory and editorial boards, Dr. Modell has published over 50 peer-reviewed articles in the medical and scientific literature spanning several therapeutic areas. In addition to psychiatry, his publications span anesthesiology, neurology, nuclear medicine, and pharmacology.

As Vice President and Senior Medical Officer at Rho, Dr. Modell provides medical and scientific strategy and operational expertise across multiple therapeutic areas. His responsibilities include ensuring the integrity and safety of clinical trials (as well as the welfare of trial subjects), maximizing study efficiency and validity, signal detection, regulatory approvability, and the ultimate benefit to patients.